BOSTON and ATLANTA, April 18, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson s.
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 Inhibikase Therapeutics, Inc. , a.
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing.